Login
$HURA
$1.35 +$0.02 (1.5%) After hours

$HURA SEC Filings

Filed On Filing
13 Nov 2026 10-Q
13 Nov 2026 8-K: Results of Operations and Financial Condition

TAMPA, Fla., Nov. 13, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial re...

06 Nov 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

16 Oct 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

24 Sep 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

17 Sep 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

17 Sep 2026 8-K/A: Departure/Election of Directors or Officers; Compensation

(a) Purpose. The TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan (the “Plan”) is intended to provide equity-based and cash incentive awards that qualify as employment inducement awards under the Nasdaq Rule. The Plan is in...

16 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

(a) Purpose. The TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan (the “Plan”) is intended to provide equity-based and cash incentive awards that qualify as employment inducement awards under the Nasdaq Rule. The Plan is in...

04 Sep 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

28 Aug 2026 SCHEDULE 13D/A
21 Aug 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

19 Aug 2026 8-K: Unregistered Sales of Equity Securities; Submission of Matters to a Vote of Security Holders

As previously disclosed in the Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) with the Securities and Exchange Commission on April 22, 2026, on April 21, 2026, the Company entered into a Loan Agreement (the ...

14 Aug 2026 10-Q
14 Aug 2026 8-K: Results of Operations and Financial Condition

TAMPA, Fla., August 14, 2026 -- TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial ...

13 Aug 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

29 Jul 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

09 Jul 2026 ARS
09 Jul 2026 DEFA14A
09 Jul 2026 Proxy statement: annual meeting on August 18, 2026

CEO pay $4.0M, down 34% · say-on-pay vote

07 Jul 2026 8-K: Creation of a Direct Financial Obligation

As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender. The Loan Agreement provides for a revolving credit facil...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support